Clinical Trial

Rebalancing the Fat Content of the Heart and Muscles

Study acronym: Re-CHARM
Recruiting
View on ClinicalTrials.gov →
Summary
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-03.
Status change: Not Yet Recruiting → Recruiting 2026-04-29
Trial Details
NCT Number NCT07065383
Lead Sponsor University of Aberdeen
Collaborators: NHS Grampian
Conditions Diabetes Mellitus Type 2
Enrollment 60 participants
Start Date 2025-08-01
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30